{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:54:10Z","timestamp":1792252450102,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tjpad.2026.100686","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:30:39Z","timestamp":1792222239000},"page":"100686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline MRI markers and clinical outcomes during anti-amyloid \u03b2 therapy: A real-world study in a Japanese dementia center"],"prefix":"10.1016","volume":"13","author":[{"given":"Yuki","family":"Kujuro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7163-2680","authenticated-orcid":false,"given":"Teppei","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Moritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Katai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9754-2632","authenticated-orcid":false,"given":"Hidenori","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tjpad.2026.100686_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70652","article-title":"Real-world lecanemab adoption in Japan 1 year after launch: insights from 311 specialists on infrastructure and reimbursement barriers","volume":"21","author":"Sato","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100686_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100686_bib0004","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100686_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100686_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13195-025-01912-6","article-title":"Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data","volume":"17","author":"Noguchi-Shinohara","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100686_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70750","article-title":"Lecanemab treatment for Alzheimer's disease of varying severities and associated plasma biomarkers monitoring: a multi-center real-world study in China","volume":"21","author":"Chen","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13195-025-01886-5","article-title":"Real-world application of lecanemab in early-stage Alzheimer's disease: a single-center prospective cohort analysis","volume":"17","author":"Shang","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100686_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100686_bib0014","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3174\/ajnr.A2935","article-title":"Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated Lie algebra improves the diagnosis of probable Alzheimer disease","volume":"33","author":"Matsuda","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100686_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100686_bib0016","series-title":"Prescribing information","year":"2024"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13063-018-3108-3","article-title":"The correlation between baseline score and post-intervention score, and its implications for statistical analysis","volume":"20","author":"Clifton","year":"2019","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100686_bib0018","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100686_bib0019","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular neurology considerations for antiamyloid immunotherapy: a science advisory from the American Heart Association","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100686_bib0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.tjpad.2026.100686_bib0021","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1212\/WNL.0000000000004539","article-title":"Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100686_bib0022","doi-asserted-by":"crossref","first-page":"e1086","DOI":"10.1212\/WNL.0000000000007039","article-title":"Distribution of cerebral microbleeds in the East and West: individual participant meta-analysis","volume":"92","author":"Yakushiji","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100686_bib0023","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100686_bib0024","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1161\/STROKEAHA.113.002267","article-title":"Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds","volume":"44","author":"Cheng","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100686_bib0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3174\/ajnr.A1355","article-title":"MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength","volume":"30","author":"Nandigam","year":"2009","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726002098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:33:56Z","timestamp":1792251236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726002098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2274580726002098"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100686","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline MRI markers and clinical outcomes during anti-amyloid \u03b2 therapy: A real-world study in a Japanese dementia center","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100686"}}